Terray Therapeutics

Terray Therapeutics integrates nanotechnology-based ultra-high-throughput chemistry with AI to discover small molecule drugs at unprecedented scale. The company's platform generates millions of molecules per month using microarray-based nanotechnology, creating the world's largest proprietary drug-target interaction dataset — 50 times larger than all publicly available chemistry data. This massive experimental foundation powers AI models for potency prediction and molecular design.

$226M

Total raised

Ultra-high-throughput experimental platform using nanotechnology-based microarrays to synthesize and test millions of molecules per month. This generates the world's largest proprietary drug-target interaction dataset, which trains AI models (including TerraBind/EMMI Predict) for binding affinity prediction and generative molecular design.